TABLE III.
ROI | CMOD DV | CMOD BP | ||||
---|---|---|---|---|---|---|
Pre-treatment | Post-treatment | W; p-value | Pre-treatment | Post-treatment | W; p-value | |
CER | 0.44 ± 0.12 | 0.51 ± 0.11 | −0.73;0.56 | n.a. | n.a. | n.a. |
MTCa | 7.50 ± 2.98 | 6.81 ± 1.95 | −0.73;0.63 | 15.67 ± 2.74 | 11.36 ± 4.21 | −1.46;0.25 |
RN | 2.03 ± 0.68 | 2.11 ± 0.50 | −0.11;1.00 | 3.68 ± 1.62 | 3.21 ± 1.09 | −0.52;0.69 |
LLO | 2.86 ± 0.85 | 3.14 ± 0.88 | −0.52;0.69 | 5.47 ± 1.40 | 5.17 ± 1.34 | −0.73;0.56 |
RLO | 2.78 ± 0.74 | 3.11 ± 0.53 | −0.1.15;0.31 | 5.41 ± 1.59 | 5.21 ± 1.28 | −0.31;0.84 |
OCC-PC | 1.79 ± 0.60 | 2.00 ± 0.50 | −0.94; 0.44 | 3.06 ± 1.20 | 2.95 ± 0.78 | −0.31;0.84 |
PCG | 2.29 ± 0.69 | 2.60 ± 0.49 | −0.94;0.44 | 4.17 ± 0.96 | 4.17 ± 1.01 | −0.11;1.00 |
two subjects’s MTC-BP data were excluded because the model failed to provide stable curve fits for this region’s time-activity concentrations.
Abbreviations as in table II